Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccination is progressing globally. Several adverse reactions have been reported with vaccination against COVID-19. It is unknown whether adverse reactions to COVID-19 vaccination are severe in individuals with allergies. We administered the COVID-19 vaccine to the medical staff at Yamagata University Hospital from March to August 2021. Subsequently, we conducted an online questionnaire-based survey to investigate the presence of allergy and adverse reactions after vaccination and examined the association between allergy and adverse reactions after immunization.
Responses were collected from 1586 subjects after the first vaccination and 1306 subjects after the second administration of the BNT162b2 mRNA COVID-19 vaccine. Adverse reactions included injection site pain, injection site swelling, fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia. The frequency and severity of most adverse reactions were higher after the second vaccination compared to the first. The frequency of some adverse reactions and their severity were higher, and the duration of symptoms was longer in subjects with allergies than in subjects without allergies. Although several participants visited the emergency room for treatment after the first and second vaccinations, nobody was diagnosed with anaphylaxis.
Given the serious consequence of COVID-19 and the reported high efficacy of this vaccine against this disease, we conclude that vaccination of allergic individuals is generally recommended.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; SI has received lecture fees from Pfizer Japan Inc., and KYORIN Pharmaceutical Co.,Ltd. MW has received research grant and lecture fee from Pfizer Japan Inc. SS has received donation course for medical science and education from NISSIN PHARMACEUTICAL CO., LTD. no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; SI has received lecture fees from Pfizer Japan Inc., and KYORIN Pharmaceutical Co.,Ltd. MW has received research grant and lecture fee from Pfizer Japan Inc. SS has received donation course for medical science and education from NISSIN PHARMACEUTICAL CO., LTD. no other relationships or activities that could appear to have influenced the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethics Committee of the Yamagata University Faculty of Medicine
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; SI has received lecture fees from Pfizer Japan Inc., and KYORIN Pharmaceutical Co.,Ltd. MW has received research grant and lecture fee from Pfizer Japan Inc. SS has received donation course for medical science and education from NISSIN PHARMACEUTICAL CO., LTD. no other relationships or activities that could appear to have influenced the submitted work.
Data Availability
All data will not be made public in principle because some parts contain personal information of the subjects. For ethical reasons, data that is not suitable for public disclosure may be made available only upon request.
